Effect of a multitarget therapy with prednisolone, mycophenolate mofetil, and tacrolimus in a patient with type B insulin resistance syndrome complicated by lupus nephritis. Issue 1 (15th October 2021)

• Record Type: Journal Article
• Authors: Temmoku, Jumpei; Asano, Tomoyuki; Saito, Kenji; Matsumoto, Haruki; Fujita, Yuya; Furuya-Yashiro, Makiko; Matsuoka, Naoki; Oda, Akira; Tanabe, Hayato; Sato, Shuzo; Shio-Yano, Kiori; Sasajima, Tomomi; Kiko, Yuichiro; Kobayashi, Hiroko; Watanabe, Hiroshi; Shimabukuro, Michio; Migita, Kiyoshi
• Is Part Of: Modern rheumatology case reports. Volume 6:Issue 1(2022)
• Page Start: 41
• Page End: 46
• Publication Date: 2021-10-15
• Subjects: Type B insulin resistance syndrome -- lupus nephritis -- multitarget therapy -- mycophenolate mofetil -- tacrolimus; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1093/mrcr/rxab020
• Languages: English
• ISSNs: 2472-5625

Abstract

ABSTRACT: Type B insulin resistance syndrome (TBIR) is a rare autoimmune disease characterised by autoantibodies targeting insulin receptors. TBIR is often complicated by systemic lupus erythematosus (SLE). We describe the case of a 59-year-old Japanese man with TBIR complicated with lupus nephritis (LN), who presented with nephrotic syndrome and severe hypoglycaemia. Treatment with prednisolone (PSL), mycophenolate mofetil (MMF), and tacrolimus (TAC) resulted in improved SLE activity and glucose intolerance with the reduction of anti-insulin receptor autoantibodies. To the best of our knowledge, this is the first reported case of TBIR complicated with LN that was successfully treated using multitarget therapy with PSL, MMF, and TAC.